Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy before it can consider approval.

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the drug rose by more than 160% last year to reach $602 million, placing it on a ...

Pharma has so far been exempted from Trump's tariff blitz, which imposed a flat rate of 10% on imports from 5th April and much higher levels on countries deemed to have the greatest trade surplus with ...

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of disease. However, cell and gene therapy (CGT) is ...

Medical affairs teams produce evidence-based, non-promotional scientific content for healthcare professionals (HCPs), while marketing teams develop engaging materials on overlapping topics such as ...

The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...